Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.56 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20063792 | 1.00 | ANPEP (0.56) | ANPEPSLC18A3IDO1SIGMAR1PLAU | |
| SCHEMBL29687690 | 1.00 | ANPEP (0.56) | ANPEPSLC18A3IDO1SIGMAR1PLAU | |
| SCHEMBL20095994 | 1.00 | ANPEP (0.56) | ANPEPSLC18A3IDO1SIGMAR1PLAU | |
| SCHEMBL1990443 | 1.00 | ANPEP (0.56) | ANPEPSLC18A3IDO1SIGMAR1PLAU | |
| Naphthalene SCHEMBL8201172 | 0.92 | ANPEP (0.50) | ANPEPSLC18A3IDO1SIGMAR1 | |
| SCHEMBL6932695 | 0.82 | ANPEP (0.47) | ANPEPSLC18A3IDO1SIGMAR1 | |
| SCHEMBL11355392 | 0.82 | ANPEP (0.68) | ANPEPSLC18A3IDO1PLAU | |
| SCHEMBL22893170 | 0.82 | ANPEP (0.47) | ANPEPSLC18A3IDO1SIGMAR1 | |
| SCHEMBL3996873 | 0.82 | ANPEP (0.68) | ANPEPSLC18A3IDO1PLAU | |
| SCHEMBL9515317 | 0.82 | ANPEP (0.68) | ANPEPSLC18A3IDO1PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2500407-B1 | Cleaning formulations and method of using the cleaning formulations | AIR PROD & CHEM (US) | 2017-07-19 | — | — | EP | claimed |
| WO-2000022662-A1 | INHIBITION OF TITANIUM CORROSION | EKC TECHNOLOGY, LTD (GB) | 2000-04-20 | — | — | WO | claimed |
| US-20250381198-A1 | MIDAZOLAM AND KETAMINE FOR ENHANCED SEDATION | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2025-12-18 | — | — | US | disclosed |
| US-20240415848-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2024-12-19 | — | — | US | disclosed |
| US-12083126-B2 | Pharmaceutical compositions and methods for anesthesiological applications | MELT PHARMACEUTICALS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| CN-111712241-B | Sigma-1 receptor agonist systolic blood pressure therapy | 阿纳韦克斯生命科学公司 | 2024-02-13 | — | — | CN | disclosed |
| US-20220249510-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2022-08-11 | — | — | US | disclosed |
| US-20220031664-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTIEMETICS AND ALPHA-2-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USING THE SAME FOR ANESTHESIOLOGICAL APPLICATIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2022-02-03 | — | — | US | disclosed |
| US-20210085691-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2021-03-25 | — | — | US | disclosed |
| US-20200297734-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2020-09-24 | — | — | US | disclosed |
| US-10391102-B2 | Pharmaceutical compositions and methods for anesthesiological applications | MELT PHARMACEUTICALS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| WO-2012171114-A1 | SYNTHETIC EPIGALLOCATECHIN GALLATE (EGCG) ANALOGS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2012-12-20 | — | — | WO | disclosed |
| US-20110152210-A1 | POLYPHENOL COMPOUNDS FOR INHIBITING PROTEASOME AND USES THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2011-06-23 | — | — | US | disclosed |
| EP-1934159-B1 | METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS | BASF SE (DE) | 2009-03-25 | — | — | EP | disclosed |
| US-20090030235-A1 | METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS | BASF SE (DE) | 2009-01-29 | — | — | US | disclosed |
| WO-2000022662-A1 | INHIBITION OF TITANIUM CORROSION | EKC TECHNOLOGY, LTD (GB) | 2000-04-20 | — | — | WO | disclosed |
| WO-2000022662-A1 | INHIBITION OF TITANIUM CORROSION | EKC TECHNOLOGY, LTD (GB) | 2000-04-20 | — | — | WO | disclosed |
| EP-0145447-A1 | Process for epoxidizing vicinal diols | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1985-06-19 | — | — | EP | disclosed |
| US-4111917-A | POLYURETHANES | W. R. GRACE & CO. (US) | 1978-09-05 | — | — | US | disclosed |
| US-4029676-A | ANTIADRENERGIC, ANTIFIBRILLATORY | E. R. SQUIBB & SONS, INC. (US) | 1977-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220249510-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS | GRIN3A, OPRK1, GRIN2B | ANPEP 2857/4885SLC18A3 399/4885IDO1 1142/4885 |
| US-10391102-B2 | Pharmaceutical compositions and methods for anesthesiological applications | GRIN2B, GRIN3A, GABRA5 | ANPEP 2849/4885SLC18A3 780/4885IDO1 896/4885 |
| US-20240415848-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS | GRIN3A, OPRK1, GRIN2B | ANPEP 2857/4885SLC18A3 399/4885IDO1 1142/4885 |
| US-20200297734-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS | GRIN3A, OPRK1, GRIN2B | ANPEP 2857/4885SLC18A3 399/4885IDO1 1142/4885 |
| US-20210085691-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS | GRIN2B, GRIN3A, GRIN1 | ANPEP 2211/4885SLC18A3 471/4885IDO1 869/4885 |
| US-20250381198-A1 | MIDAZOLAM AND KETAMINE FOR ENHANCED SEDATION | KCNA3, OPRK1, KCNA7 | ANPEP 3405/4885SLC18A3 335/4885IDO1 2848/4885 |
| US-20090030235-A1 | METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS | ADH5, ADH1C, ADH1A | ANPEP 710/4885SLC18A3 784/4885IDO1 2146/4885 |
| US-12083126-B2 | Pharmaceutical compositions and methods for anesthesiological applications | GRIN3A, OPRK1, GRIN2B | ANPEP 2857/4885SLC18A3 399/4885IDO1 1142/4885 |
| US-20110152210-A1 | POLYPHENOL COMPOUNDS FOR INHIBITING PROTEASOME AND USES THEREOF | PSMC1, PSME1, PSMB1 | ANPEP 1096/4885SLC18A3 4526/4885IDO1 3112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.